GlassScriptPhysician profile
Rachel E Agustines
NPI 1386617306
$16,175.35
in general payments reported to CMS, 2019-2025
33 companies · $4,252 in 2025
The $4,252 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,007 · 2021: $1,783 · 2022: $1,059 · 2023: $3,596 · 2024: $3,139 · 2025: $4,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,974.73 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,279.13 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,822.65 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,440.55 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $1,312.44 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $1,181.57 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,166.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $923.29 | 2023-2025 | Caplyta |
| Alkermes, INC. | $768.66 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $589.81 | 2019-2022 | |
| Tris Pharma INC | $583.69 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $476.28 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $391.88 | 2019-2025 | Rexulti |
| Noven Therapeutics, LLC | $372.08 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $339.48 | 2020-2025 | Trintellix |
| Bausch Health US, LLC | $330.22 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $307.54 | 2019-2025 | Spravato, Invega, Invega Trinza |
| Corium, LLC | $278.99 | 2021-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $272.00 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $260.25 | 2025 | Cobenfy |
| Almatica Pharma LLC | $229.48 | 2021-2025 | Loreev Xr, Gralise |
| Allergan, INC. | $206.90 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $100.84 | 2019-2021 | |
| Biogen, INC. | $95.00 | 2023 | |
| Collegium Pharmaceutical, INC. | $74.50 | 2025 | Jornay Pm |
| Eisai INC. | $62.67 | 2020-2021 | |
| Neos Therapeutics, LP | $61.66 | 2019-2025 | Adzenys Xr-Odt |
| Shire North American Group INC | $57.31 | 2019 | |
| Sage Therapeutics, LLC | $56.51 | 2025 | Zurzuvae |
| Livanova USA, INC. | $48.12 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.78 | 2020 | |
| Harmony Biosciences LLC | $22.42 | 2020 | |
| Alfasigma USA, INC. | $17.94 | 2020 | |
| Merck Sharp & Dohme LLC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Agustines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.